Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
| Episode | Date |
|---|---|
|
Key Challenges Facing Neurology in the Year Ahead
|
Mar 13, 2026 |
|
162: Breaking Down INFUSE Trial Data and Real-World Eptinezumab Use
|
Mar 06, 2026 |
|
161: Clinical Takeaways From 2026 International Stroke Conference
|
Feb 27, 2026 |
|
160: Early Pathology, Biomarkers, and the Next Phase of DMD Care
|
Feb 20, 2026 |
|
Special Episode: The 2026 AHA/ASA Guideline for Early Management of Acute Ischemic Stroke
|
Feb 13, 2026 |
|
159: Key Practice Takeaways From the New AAN Functional Seizure Guidelines
|
Jan 23, 2026 |
|
158: Bexicaserin, the PACIFIC Trial, and Treating Developmental Epileptic Encephalopathies
|
Jan 09, 2026 |
|
157: Clinical Advances and Unanswered Questions in Narcolepsy
|
Dec 26, 2025 |
|
156: Building Better Mood and Behavior Care for Parkinson Disease
|
Dec 12, 2025 |
|
155: Understanding Variability in Infantile Spasms Care
|
Nov 28, 2025 |
|
154: NEALS 2025: Takeaways That Matter for ALS Care
|
Nov 14, 2025 |
|
153: Overviewing the 2025 Alzheimer's Association's Blood-Based Biomarker Guidelines
|
Oct 31, 2025 |
|
152: Building Safer, Smarter, and More Personalized Epilepsy Care
|
Oct 17, 2025 |
|
151: ECTRIMS 2025 Debrief: Precision MS & What’s Next with Daniel Ontaneda
|
Oct 03, 2025 |
|
150: Rethinking Parkinson’s Care: Prevention, Equity, and Access to Treatment
|
Sep 19, 2025 |
|
Special Episode: Understanding Fremanezumab's Expanded Indication in Pediatric Migraine
|
Sep 12, 2025 |
|
149: Overviewing Consensus Guidelines to Standardize Gene Therapy Care in Duchenne
|
Sep 05, 2025 |
|
148: Navigating Transition: Supporting Young Adults With Epilepsy Into Adult Care
|
Aug 22, 2025 |
|
147: Improving Quality of Life in Movement Disorders Through Nonmotor Symptom Management
|
Aug 08, 2025 |
|
146: Overviewing Donanemab’s New Dosing Regimen: Lowering ARIA Risk in Alzheimer Care
|
Jul 25, 2025 |
|
Breaking Down the FDA’s Latest Migraine Therapy Approvals with Dr. Stewart Tepper
|
Jul 18, 2025 |
|
145: Rewiring Stroke Recovery: What the Glymphatic System Can Teach Us
|
Jul 11, 2025 |
|
144: Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What’s Ahead
|
Jun 27, 2025 |
|
143: Bemdaneprocel and the Future of Cell Therapy in Parkinson Disease
|
Jun 13, 2025 |
|
142: World MS Day: Raising Awareness, Evolving Care, and Empowering Patients
|
May 30, 2025 |
|
141: Refining TSC Care: Phenotyping, Clustering, and Clinical Impact
|
May 16, 2025 |
|
140: Down Syndrome and Alzheimer’s: Clinical Trials, Equity, and Patient-Centered Progress
|
May 02, 2025 |
|
139: Sleep and Seizures: Emerging Insights From AAN 2025
|
Apr 18, 2025 |
|
138: Training the Next Generation of Neurology Nurse Practitioners
|
Apr 04, 2025 |
|
Special Episode: What Apomorphine Infusion Approval Means for Parkinson Disease Care
|
Mar 27, 2025 |
|
137: Advancing Neuromuscular Care and Research
|
Mar 21, 2025 |
|
Special Episode: FDA Approves Tenecteplase for Acute Ischemic Stroke
|
Mar 12, 2025 |
|
136: Raising Epilepsy Awareness for Purple Day
|
Mar 07, 2025 |
|
135: Invaluable Role of Social Support in Narcolepsy and Idiopathic Hypersomnia Care
|
Feb 21, 2025 |
|
134: Previewing the 2025 ACTRIMS Forum
|
Feb 07, 2025 |
|
133: Clinical Guidance on Neurostimulation for Lennox-Gastaut Syndrome
|
Jan 24, 2025 |
|
132: Aiding Diagnosis of Synucleinopathies Through SAAmplify-aSYN Biomarker Test
|
Jan 10, 2025 |
|
131: Neurology Unwrapped: 2024’s Most Intriguing Conversations
|
Dec 27, 2024 |
|
130: The Promise Behind Cell Therapy Approaches in Epilepsy
|
Dec 13, 2024 |
|
129: Implications of the 2024 AASM Guidelines for Restless Legs Syndrome
|
Nov 29, 2024 |
|
128: Machine Learning Algorithms to Predict Seizure Control in Epilepsy Surgery
|
Nov 15, 2024 |
|
127: Adapting Neuromuscular and Electrodiagnostic Medicine Education for Modern Learners
|
Nov 01, 2024 |
|
Special Episode: FDA Approves Sodium Oxybate for Pediatric Narcolepsy
|
Oct 23, 2024 |
|
126: Therapeutic Potential of ATH434 in Multiple System Atrophy
|
Oct 18, 2024 |
|
125: Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis
|
Oct 04, 2024 |
|
124: Therapeutic Updates and Progress in Treating Becker Muscular Dystrophy
|
Sep 20, 2024 |
|
123: Previewing Cleveland Clinic's Epilepsy Summit
|
Sep 06, 2024 |
|
122: RNA Therapeutics, Mivelsiran, and Treating Alzheimer Disease
|
Aug 23, 2024 |
|
121: Understanding the Potential Cardiovascular Benefits of Low-Sodium Oxybate
|
Aug 09, 2024 |
|
115: Expanding Access to Ublituximab and AntiCD20s for Multiple Sclerosis
|
Jul 31, 2024 |
|
120: Improving Gait in Multiple Sclerosis Through the Neural Sleeve
|
Jul 26, 2024 |
|
119: Utilizing the Syn-One Test to Diagnose Parkinson Disease
|
Jul 12, 2024 |
|
Special Episode: FDA Approves Donanemab for Early Symptomatic Alzheimer Disease
|
Jul 09, 2024 |
|
118: Gaining Patient Perspectives on Impact of Narcolepsy
|
Jun 28, 2024 |
|
117: 2024 Consortium of Multiple Sclerosis Centers Annual Meeting Highlights
|
Jun 14, 2024 |
|
116: Understanding Vorasidenib's Therapeutic Benefit on Neurocognition, Seizure Control in Diffuse Gliomas
|
May 31, 2024 |
|
114: Phase 3 PHOENIX Study, AMX0035, and Amylyx's Future Drug Development
|
May 03, 2024 |
|
Special Episode: FDA Approval of Diazepam Buccal Film for Pediatric Seizures
|
May 01, 2024 |
|
113: Lessons Learned in Alzheimer Drug Development
|
Apr 19, 2024 |
|
112: Exploring Dimethyl Fumarate to Treat Friedreich Ataxia
|
Apr 05, 2024 |
|
Special Episode: FDA Approval of Givinostat for Duchenne Muscular Dystrophy
|
Mar 29, 2024 |
|
111: Reviewing ACTRIMS 2024
|
Mar 22, 2024 |
|
110: Differential Diagnosis of Sleep Disorders and Hypersomnias
|
Mar 08, 2024 |
|
109: AB126, Exosomes, and Cerebroprotection for Stroke
|
Feb 23, 2024 |
|
108: Advancing the Genetic Pool of Parkinson Disease
|
Feb 09, 2024 |
|
107: Revealing Mechanisms of Sudden Unexplained Death in Toddlers
|
Jan 26, 2024 |
|
106: Potential Role of Stathmin-2 in Amyotrophic Lateral Sclerosis
|
Jan 12, 2024 |
|
105: Recapping Conversations in Neurology From 2023
|
Dec 29, 2023 |
|
104: Effects of Once-Nightly Sodium Oxybate on Narcolepsy Type 1 and 2
|
Dec 15, 2023 |
|
103: Advancing Epilepsy Care and Seizure Localization in Pediatrics
|
Dec 01, 2023 |
|
102: Potential of Gamma Sensory Stimulation in Alzheimer Disease
|
Nov 17, 2023 |
|
Special Episode: FDA Greenlights Vamorolone for Duchenne Muscular Dystrophy
|
Nov 07, 2023 |
|
101: Ways to Enhance Neuromodulation in Parkinsonism
|
Nov 03, 2023 |
|
Special Episode: FDA Approves Zilucoplan for Myasthenia Gravis
|
Oct 23, 2023 |
|
100: 2023 ECTRIMS-ACTRIMS Meeting Highlights
|
Oct 20, 2023 |
|
99: Understanding AMX0035's Potential in Progressive Supranuclear Palsy
|
Oct 05, 2023 |
|
98: Uncovering Phenotypical Features of Narcolepsy Type 1
|
Sep 22, 2023 |
|
97: Identifying Gaps in Access to Parkinson Disease Care
|
Sep 08, 2023 |
|
96: Complexities With Cognitive Screening in Primary Care Settings
|
Aug 25, 2023 |
|
Special Episode: Addition of Valbenazine to Treat Huntington Disease Chorea
|
Aug 21, 2023 |
|
95: Expanding Potential for Long-Term Treatment in SMA
|
Aug 11, 2023 |
|
94: The Discussion Surrounding Lecanemab's Approval for Alzheimer Disease
|
Jul 28, 2023 |
|
93: Caring for Women With Parkinson Disease
|
Jul 14, 2023 |
|
92: Highlights From the 2023 CMSC, SLEEP, AHS, and ATMRD Annual Meetings
|
Jun 30, 2023 |
|
Special Episode: SRP-9001 Approved As First Gene Therapy for Duchenne Muscular Dystrophy
|
Jun 22, 2023 |
|
91: Assessing the Landscape of Sleep Disorder Care
|
Jun 16, 2023 |
|
90: Raising Stroke Awareness and Improving Clinical Care
|
Jun 02, 2023 |
|
89: Potential of CNM-Au8 Gold Nanocrystals to Treat ALS
|
May 19, 2023 |
|
88: 2023 AAN Annual Meeting Highlights
|
May 05, 2023 |
|
Special Episode: Tofersen Approved for SOD1 ALS
|
Apr 25, 2023 |
|
87: Severe Multiple Sclerosis and the CASA-MS Study
|
Apr 21, 2023 |
|
86: Pimavanserin and Atypical Antipsychotics to Treat Parkinson Disease Psychosis
|
Apr 07, 2023 |
|
85: Impact of Narcolepsy on Social Relationship Health in Adolescents
|
Mar 24, 2023 |
|
Special Episode: Trofinetide Approved for Rett Syndrome
|
Mar 13, 2023 |
|
84: Parkinson Disease Education for Community Providers
|
Mar 10, 2023 |
|
83: The ARISE Study and Using DMTs in RIS
|
Feb 24, 2023 |
|
82: Managing Seizures After Ischemic Stroke
|
Feb 10, 2023 |
|
81: Widening the Therapeutic Window in Parkinson Disease
|
Jan 27, 2023 |
|
80: Advancing Treatment for Rare Neuromuscular Disorders
|
Jan 13, 2023 |
|
Special Episode: Lecanemab Approved for Alzheimer Disease
|
Jan 09, 2023 |
|
79: A New Monoclonal for Alzheimer Disease
|
Dec 16, 2022 |
|
78: A Virtual Reality Platform for Parkinson Disease
|
Dec 02, 2022 |
|
77: A New Era of Myasthenia Gravis Treatment
|
Nov 18, 2022 |
|
76: ECTRIMS 2022 and the Latest in MS Advances
|
Nov 04, 2022 |
|
75: Focusing on the Future of Neurology
|
Oct 21, 2022 |
|
74: Prescription Digital Therapeutics for Insomnia
|
Oct 07, 2022 |
|
73: The Role of Palliative Care in Neurology
|
Sep 23, 2022 |
|
72: Updates in Epilepsy Treatment
|
Sep 09, 2022 |
|
71: Pediatric Sleep and School Start Times
|
Aug 26, 2022 |
|
70: Raising Awareness of Acute Flaccid Myelitis
|
Aug 12, 2022 |
|
69: The Widespread Effects of DMT Waste in Multiple Sclerosis
|
Jul 29, 2022 |
|
68: Updates in Essential Tremor Care
|
Jul 15, 2022 |
|
67: Mental Health and Advocacy in Pediatric Migraine
|
Jul 01, 2022 |
|
66: 2022 SLEEP Annual Meeting Highlights
|
Jun 17, 2022 |
|
Special Episode: Aducanumab and Anti-Amyloid-ß, One Year Later
|
Jun 07, 2022 |
|
65: 2022 CMSC Annual Meeting Highlights
|
Jun 04, 2022 |
|
64: Genetics, Advocacy, and Big Data in ALS
|
May 20, 2022 |
|
63: Moving Migraine Toward Personalized Care
|
May 06, 2022 |
|
62: Advanced Therapeutics in Parkinson and Movement Disorders
|
Apr 22, 2022 |
|
61: 2022 AAN Annual Meeting Highlights
|
Apr 09, 2022 |
|
Special Episode: Ganaxolone Approved for CDD, Fenfluramine Approved for LGS
|
Mar 30, 2022 |
|
60: Improving Care and Raising Awareness for NMOSD
|
Mar 25, 2022 |
|
Special Episode: Heart Health in Narcolepsy
|
Mar 18, 2022 |
|
59: AASM's Push to End Daylight Saving Time
|
Mar 11, 2022 |
|
58: Addressing Parkinson Disease Virtually With Prime PD
|
Feb 25, 2022 |
|
57: Invisible Symptoms: Cognition and MS
|
Feb 11, 2022 |
|
56: Epstein-Barr Virus's Relationship With Multiple Sclerosis
|
Jan 28, 2022 |
|
55: Treating Headache in the Emergency Department
|
Jan 14, 2022 |
|
Special Episode: Daridorexant Approved for Insomnia
|
Jan 11, 2022 |
|
54: The Shortage of Neurologists
|
Dec 31, 2021 |
|
53: A Landmark Year for Alzheimer Disease
|
Dec 17, 2021 |
|
52: Treating Pediatric Migraine
|
Dec 03, 2021 |
|
51: The State of Sleep Medicine
|
Nov 19, 2021 |
|
50: Genetic Testing for Huntington Disease
|
Nov 05, 2021 |
|
49: Altering the View of MS With a Topographical Model
|
Oct 22, 2021 |
|
48: RapidAI's Effect on Stroke Imaging
|
Oct 08, 2021 |
|
47: Incorporating Physical Therapy Into MS Care
|
Sep 24, 2021 |
|
46: Tackling Barriers to Migraine Care
|
Sep 10, 2021 |
|
45: Small Victories: Advancing Care in Parkinson Disease
|
Aug 27, 2021 |
|
44: AHA/ASA Updates to the Stroke Care Model
|
Aug 13, 2021 |
|
43: Is Telehealth Here to Stay for Alzheimer Disease Care?
|
Jul 30, 2021 |
|
42: The Importance of Sleep for Overall Health
|
Jul 16, 2021 |
|
41: Consensus MRI Guidelines for MS
|
Jul 02, 2021 |
|
40: SLEEP 2021: Topline Data, Telemedicine, and Takeaways
|
Jun 18, 2021 |
|
39: A Controversial FDA Decision
|
Jun 11, 2021 |
|
38: Advancing MS Care and Awareness
|
Jun 04, 2021 |
|
37: The Impact of Awareness Efforts in ALS
|
May 21, 2021 |
|
36: Zavegepant and the Gepant Class for Migraine Care
|
May 07, 2021 |
|
35: Highlights From the AAN Annual Meeting
|
Apr 30, 2021 |
|
34: Hope and the Huntington Disease Pipeline
|
Apr 23, 2021 |
|
33: Problem Recognition: Cerebral Palsy Diagnosis
|
Apr 09, 2021 |
|
32: The Gaps in Migraine Care for Women
|
Mar 26, 2021 |
|
31: The Pipeline Pendulum in Parkinson Disease
|
Mar 12, 2021 |
|
30: Cognitive Behaviorial Therapy for Insomnia
|
Feb 26, 2021 |
|
29: Developing A Seizure Action Plan
|
Feb 12, 2021 |
|
28: The Multiple Sclerosis Patient Journey
|
Jan 29, 2021 |
|
27: Short, Sudden, Strange, Similar Spells
|
Jan 15, 2021 |
|
26: Digital Approaches to Comprehensive Care in MS
|
Jan 01, 2021 |
|
25: 2020 Wrap Up: Silver Linings
|
Dec 31, 2020 |
|
24: Aducanumab and Alzheimer Disease Clinical Trials
|
Dec 18, 2020 |
|
23: Real-World Acute Migraine Care
|
Dec 04, 2020 |
|
22: Capitalizing on Collaboration in Neurology Care
|
Nov 20, 2020 |
|
21: How Social Isolation Can Affect Disease Severity
|
Nov 06, 2020 |
|
20: Taking Steps to Advance Sleep Care
|
Oct 23, 2020 |
|
19: The Vascular Implications of Alzheimer Disease
|
Oct 09, 2020 |
|
18: Preventing Tonic-Clonic Seizures in Refractory Epilepsy
|
Sep 25, 2020 |
|
17: The Metamorphosis of Migraine: Discovery and Development
|
Sep 11, 2020 |
|
16: Personalizing Our Approach to Medication Adherence in Parkinson Disease
|
Aug 28, 2020 |
|
15: A New Approval: The SMA Treatment Landscape
|
Aug 14, 2020 |
|
14: Trends in the Alzheimer Clinical Pipeline
|
Jul 31, 2020 |
|
13: Sequencing SNPs in Huntington Disease
|
Jul 17, 2020 |
|
12: Masculinity and Multiple Sclerosis
|
Jun 26, 2020 |
|
11: Exploring the Link Between Stroke and COVID-19
|
Jun 05, 2020 |
|
10: Neurology and COVID-19: Perspectives From the Front Line
|
May 15, 2020 |
|
9: Innovation in the Parkinson Disease Pipeline
|
Apr 17, 2020 |
|
8: Adapting Neurologic Care During the COVID-19 Pandemic
|
Mar 20, 2020 |
|
7: No Relief: Rising MS Drug Prices
|
Feb 11, 2020 |
|
6: Time Is Brain: Why EMS Transport Protocols Matter
|
Jan 17, 2020 |
|
5: Gut Bacteria and the Brain: An Evolving Role in Epilepsy
|
Dec 30, 2019 |
|
4: Only the Beginning: Advancing Migraine Treatment
|
Nov 14, 2019 |
|
3: Using Technology to Broaden Stroke Care
|
Oct 03, 2019 |
|
2: Alzheimer Disease Update: Is Amyloid Really Dead?
|
Aug 19, 2019 |
|
1: State of CBD: Not All Cannabidiol Is Created Equal
|
Aug 05, 2019 |